SPEEDEL DISCLOSES CHANGES IN SIGNIFICANT SHAREHOLDINGS

Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Basel/Switzerland and Bridgewater NJ/USA, 10 July 2008
Speedel Holding Ltd. (SWX: SPPN) today announced changes of
significant shareholdings in accordance with article 20 of the Swiss
Federal Act on Stock Exchanges and Securities Trading (SESTA). The
following holders have fallen below the threshold of 3 percent of
voting rights on Speedel:
- Alice Huxley, previously 1,680,160 shares or 21.50% of voting
rights;
- Fritz Gerber, previously 879,000 shares or 11.25% of voting rights;
- Rolf Hänggi, previously 666,000 shares or 8.52% of voting rights;
- Branco Weiss, previously 490'010 shares or 6.27% of voting rights;
- Henry C. Bodmer, previously 326,000 shares or 4.17% of voting
rights.

Novartis, with a previously announced holding of 9.7%, has reported
to now hold 4,801,200 shares or 61.44% of Speedel's voting rights.

Total shares of Speedel currently sum up to 7'813'992.

About Speedel

Speedel is a public biopharmaceutical company that seeks to create
value for patients, partners and investors by developing innovative
therapies for cardiovascular and metabolic diseases. Speedel is a
world leader in renin inhibition, a promising new approach with
significant potential for treating cardiovascular diseases. Our lead
compound SPP100, Aliskiren Rasilez/ Tekturna[1]) the first-in-class
direct renin inhibitor, was in-licensed from Novartis in 1999 and
licensed-back to Novartis Pharma in 2002 for further development and
commercialisation; SPP100 was approved by the FDA in the US in March
2007, and by the EMEA in the EU in August 2007. Our pipeline covers
four different modes of action, and in addition to SPP100, includes
SPP301 (an endothelin receptor A antagonist) in Phase II, SPP200 (a
direct thrombin inhibitor) in Phase II, the next generation renin
inhibitors SPP635 (in Phase Il), SPP1148 and SPP676 (both in Phase I)
and several pre-clinical projects, including SPP2475 (aldosterone
synthase inhibitor).
Speedel develops novel product candidates through focused innovation
and smart drug development from lead identification to the end of
Phase II. We either partner with big pharma for Phase III and
commercialisation in primary-care indications, or we may ourselves
complete Phase III development in specialist indications. Candidate
compounds for development and the company's intellectual property
come from our late-stage research unit Speedel Experimenta and from
in-licensing. Our team of approximately 80 employees, including over
30 experienced pharmaceutical scientists, is located at our
headquarters and laboratories in Basel, Switzerland and at offices in
New Jersey, USA and Tokyo, Japan.
Speedel was founded in 1998 as a private company. In September 2005
the company's shares were listed on the SWX Swiss Exchange under the
symbol SPPN. Further information is available at www.speedel.com.

Forward looking statements
This press release includes forward-looking statements that involve
substantial risks and uncertainties. These forward-looking statements
are based on our current expectations and projections about future
events. All statements, other than statements of historical facts,
regarding our strategy, future operations, future financial position,
future revenues, projected costs, prospects, plans and objectives of
management are forward-looking statements. The word "may" and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying
words. We may not actually achieve the plans, intentions or
expectations described in these forward-looking statements and you
should not place undue reliance on them. There can be no assurance
that actual results of our research and development activities and
our results of operations will not differ materially from these
expectations. Factors that could cause actual results to differ from
expectations include, among others: our or our partners' ability to
develop safe and efficacious products; our or our partners' ability
to achieve positive results in clinical trials; our or our partners'
ability to obtain marketing approval and market acceptance for our
product candidates; our ability to enter into future collaboration
and licensing agreements; the impact of competition and technological
change; existing and future regulations affecting our business;
changes in governmental oversight of pharmaceutical product
development; the future scope of our patent coverage or that of third
parties; the effects of any future litigation; general economic and
business conditions, both internationally and within our industry,
including exchange rate variations; and our future financing plans.

-- Ends --

For further information please contact:

Martin Meier-Pfister
Speedel
Hirschgässlein 11
CH - 4051 Basel
Switzerland

T +41 (0) 61 206 40 00
D +41 (0) 61 206 40 90
F +41 (0) 61 206 40 01
www.speedel.com

--- End of Message ---

Speedel Holding AG
Hirschgässlein 11 Basel

ISIN: CH0021483885;
Index: SPI, SPIEX, SBIOM, SLIFE, SSCI;
Listed: Main Market in SWX Swiss Exchange;
Copyright © Hugin AS 2008. All rights reserved.